1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Hahn: FDA May Keep Some COVID-19 Reforms Post-Pandemic

 
• By Elizabeth Orr

US FDA commissioner Stephen Hahn said during an 18 June “fireside chat” that he expects closer relationships with industry and a greater reliance on postmarket data to continue even after the COVID-19 pandemic comes to an end.

Stephen Hahn in his 1st address to the FDA January 30, 2020
Stephen Hahn

Changes made in response to the COVID-19 pandemic may be here to stay at the US Food and Drug Administration, commissioner Stephen Hahn said in a presentation organized as part of the Medical Device Innovation Consortium (MDIC)’s annual public forum on 18 June.

Hahn, who was sworn in as head of the agency last December, had only a few months as commissioner under...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?